MT-303 / Myeloid Therap - LARVOL DELTA

A first-in-human study of MT-303, an innovative in vivo mRNA chimeric antigen receptor (CAR) therapy targeting GPC3, in adults with hepatocellular carcinoma. (ASCO 2025) - P1 | "Enrollment is ongoing, with safety and preliminary efficacy data expected to inform future development. ClinicalTrials.gov: NCT06478693."

IO biomarker • P1 data • Preclinical • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3

MT-303: GPC3-Targeted mRNA CAR Therapy in Hepatocellular Carcinoma (PRNewswire) - "MT-303 Clinical Trial Highlights: Design: Ongoing multicenter, open-label Phase 1 trial in advanced solid tumors expressing GPC3 (including HCC) employing a Bayesian Optimal Interval (BOIN) dose escalation....Myeloid expects to share additional clinical translational data at an upcoming medical meeting upon completion of the Phase 1 studies of MT-302 and MT-303."

Clinical protocol • P1 data • Hepatocellular Cancer

Preclinical development of MT-303, a novel LNP-formulated GPC3-specific CAR mRNA, for in vivo programming of monocytes to treat hepatocellular carcinoma (SITC 2024) - P1 | "Conclusions Here, we present a novel GPC3-targeting CAR mRNA/LNP that enables myeloid cells to directly kill tumor cells and support the establishment a cytokine-mediated immune response. MT-303 is currently being tested in phase 1 clinical trial for the treatment of HCC."

Preclinical • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3

Myeloid Therapeutics Announces SITC 2024 Oral Presentation on MT-303, the First in vivo GPC3 Targeting mRNA CAR in Human Studies for Advanced Hepatocellular Carcinoma (HCC) (PRNewswire) - "Myeloid's treatment approach focuses on selective in vivo programming of immune cell subsets with innovative off-the-shelf mRNA-encoded CAR technologies. These candidates are administered without the need for preconditioning. MT-303 arms myeloid cells with a proprietary chimeric antigen receptor that expresses specifically within myeloid cells. This approach directs and enables myeloid cells to kill GPC3 expressing cancers while orchestrating a coordinated adaptive immune anti-tumor response marked by expansion of new T cell clones."

Preclinical • Hepatocellular Cancer

Myeloid Therapeutics Initiates Patient Dosing with MT-303, a Novel GPC3 Targeting RNA CAR, in Phase 1 Study for Advanced Hepatocellular Carcinoma (HCC) (PRNewswire) - "Myeloid Therapeutics, Inc...has dosed the first patient with MT-303 in a Phase 1 study for hepatocellular carcinoma (HCC)....Dosing with MT-303 represents a significant milestone to bring advanced novel therapies to people with liver cancer."

Trial status • Gastrointestinal Cancer • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Myeloid Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Myeloid Therapeutics

Metastases • New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor